ScholarIQanswers from OpenAlex & ORCID
Wendy R. Parulekar
ResearcherPublications, citations & collaboration network
Wendy R. Parulekar is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wendy R. Parulekar have?
ScholarIQindexed works
Wendy R. Parulekar has 234 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wendy R. Parulekar have?
ScholarIQcitation count
Wendy R. Parulekar has 31,193 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wendy R. Parulekar?
ScholarIQh-index
Wendy R. Parulekar has an h-index of 49 in OpenAlex.
What is the i10-index of Wendy R. Parulekar?
ScholarIQi10-index
Wendy R. Parulekar has an i10-index of 97 in OpenAlex.
What is the ORCID of Wendy R. Parulekar?
ScholarIQorcid
The ORCID for Wendy R. Parulekar is on the source record.
What is the OpenAlex record for Wendy R. Parulekar?
ScholarIQopenalex
The OpenAlex for Wendy R. Parulekar is on the source record.
What are the most-cited papers on Wendy R. Parulekar?
ScholarIQmost cited works
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
An‐Wen Chan, Jennifer Tetzlaff, Douglas G. Altman, Andreas Laupacis, Peter C Gøtzsche, Karmela Krleža-Jerić, Asbjørn Hróbjartsson, Howard Mann, Kay Dickersin, Jesse A. Berlin, Caroline J Doré, Wendy R. Parulekar, William Summerskill, Trish Groves, Kenneth F. Schulz, Harold C. Sox, Frank W. Rockhold, Drummond Rennie, David Moher
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
A.-W. Chan, Jennifer Tetzlaff, Peter C Gøtzsche, Douglas G. Altman, H Mann, Jesse A. Berlin, Kay Dickersin, A. Hrobjartsson, Kenneth F. Schulz, Wendy R. Parulekar, Karmela Krleža-Jerić, A. Laupacis, David Moher
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott Williams, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Christopher J. Sweeney
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, J. W. Chapman, Donna Niedzwiecki, Vera J. Suman, James Moon, Vernon K. Sondak, Michael B. Atkins, Elizabeth A. Eisenhauer, Wendy R. Parulekar, Svetomir N. Markovic, Scott Saxman, John M. Kirkwood
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher Parker, Noel W. Clarke, Adrian Cook, Howard Kynaston, Peter Meidahl Petersen, Charles Catton, William Cross, John Logue, Wendy R. Parulekar, Heather Payne, Raj Persad, Holly Pickering, Fred Saad, Juliette Anderson, Amit Bahl, David Bottomley, Klaus Brasso, Rohit Chahal, Peter Cooke, Ben Eddy, Stephanie Gibbs, Chee Goh, Sandeep Gujral, Catherine Heath, Alastair Henderson, Ramasamy Jaganathan, Henrik Jakobsen, Nicholas D. James, S.K. Sundaram, Kathryn Lees, J.F. Lester, Henriette Lindberg, Julian Money‐Kyrle, Stephen Morris, Joe M. O’Sullivan, Peter Ostler, Lisa Owen, Prashant Patel, A. Pope, R. Popert, Rakesh Raman, Martin Andreas Røder, Ian Sayers, Matthew Simms, Jim Wilson, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes